Acquired Immune Deficiency Syndrome
Conditions
Interventions
treatment group:HAART+artesunate tablets
control group:HAART+artesunate tablet simulation agent
Sponsors
China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Male or female patients aged from 40 to 65years old; 2) positive test for HIV antibody confirmed by Western blot?assay; 3) less than five-year treatment of HAART, and plasma HIV viral load less than 50 copies/mL for more than 18 months; 4) CD4+T lymphocyte count between 200 cells/uL and 300 cells/uL; 5) Consent to participate in this study with signed informed consent.
Exclusion criteria
Exclusion criteria: The exclusion criteria are as follows. 1) Uncontrolled severe opportunistic infection prior to?enrollment; 2) Participating in other clinical trial within a month?prior to enrollment; 3) Receiving immunomodulator within a month; 4) WBC = 2 times of the upper limit of reference value) or kidney dysfunction (lower creatinine clearance rate); 5) Pregnant or lactating women, or women preparing for pregnancy; 6) Combined with other serious diseases (such as tumor, liver cirrhosis, cardiovascular and cerebrovascular diseases, etc.; 7) with mental or language impairment and difficulty in fully understanding the trial or failing to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute Value of CD4+ cells;Immune Reconstruction Efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD8+, CD45RA+, CD45RO+, CD4+CD28+, CD8+CD38+, CD4+CD38+;Cell proliferation and apoptosis: CD4+ki67+/CD4+, CD8+ki67+/CD8+, mitochondrial membrane potential;clinical symptoms;Viral load; | — |
Countries
China
Contacts
Public ContactWang Jian
China Academy of Chinese Medical Sciences
Outcome results
None listed